The last thing Summer Sanders expected to hear at a routine visit to her dermatologist was the word “melanoma.”
As senior director of science & education, Julie Bain leads the effort to ensure that The Skin Cancer Foundation is at the forefront of all medical and scientific information related to educating the public and health-care professionals about skin cancer prevention, early detection and treatment. She acts as chief editor and content strategist for The Skin Cancer Foundation Journal and patient education materials. She collaborates with our teams on content for use across all platforms by writing, reviewing and editing for our editorial standards. A longtime health and science writer and editor, she brought a personal history of skin cancer and a passion for the Foundation’s mission to the job in 2015. Previously, Bain served as health director for print and digital at Ladies’ Home Journal and Reader’s Digest and has written for many brands including The New York Times, Web MD, Popular Science, AARP, SELF and others. She lives in New York City, where she uses sunscreen every day and always walks on the shady side of the street.
The last thing Summer Sanders expected to hear at a routine visit to her dermatologist was the word “melanoma.”
You may have heard about a new medication that was recently FDA approved for cutaneous squamous cell carcinoma (CSCC). Libtayo (cemiplimab-rwlc) is a type of immunotherapy called a checkpoint blockade inhibitor, and it’s the first one approved to treat certain cases of CSCC. This is exciting news, so let’s break down how this new drug works and whom it might help.
Your eyes can focus on a tiny splinter in the finger of a squirming child, a stop sign in the distance or stars blinking light-years away. You can roll your eyes, flirt with them, do a double-take and express joy or despair without words. When you think about how amazing your eyes are, wouldn’t you do anything to protect them?
What happens to your biopsy tissue sample after your dermatologist ships it off to the lab?
Knowing when and what to biopsy is an important skill set for a dermatologist, but getting an accurate diagnosis is still a complicated process. That’s where a dermatopathologist comes in.
We asked Elizabeth Buzney, MD, outpatient clinical director of the Department of Dermatology at Brigham and Women’s Hospital and assistant professor of dermatology at Harvard Medical School, how to use sunscreen most effectively.
A former tanning salon employee shares a peek inside the tanning world and why she’s glad she’s seen the light.
In the summer of 2006, Kevin noticed a mole on his shoulder that seemed to have changed colors, so he went to see a dermatologist. A biopsy determined that the mole was a malignant melanoma.
At The Skin Cancer Foundation, we’ve been fighting for years to raise awareness (and motivate action) about the strong link between indoor tanning and the rise of dangerous melanoma in young women. That’s why we were thrilled to announce Allure magazine’s report about the wide availability of indoor tanning on college campuses as our 2016 Media Award winner at our Champions for Change Gala in October.
Not long after I joined The Skin Cancer Foundation a few months ago, our executive director, Dan Latore, gave me a daunting task. “We’d like to include a tribute to our founder in our annual magazine,” he said. That would be Perry Robins, MD, one of the most famous dermatologists in the world. “I think you should write it,” he said.
